Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
DARZALEX FASPRO®
DRUG
2 trials
Sponsors
Qilu Pharmaceutical Co., Ltd.
Conditions
Multiple Myeloma
Tumor
Phase 1
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
Recruiting
NCT06371534
Qilu Pharmaceutical Co., Ltd.
Tumor
Start: 2024-04-12
End: 2025-04-30
Target: 228
Updated: 2025-02-11
Phase 3
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Not yet recruiting
NCT06742138
Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma
Start: 2025-01-31
End: 2028-12-31
Target: 284
Updated: 2024-12-19